Great Bay Success Limited

Great Bay Bio (GBB), headquartered in HKSTP, is a biotech company that drives drug development using cutting-edge technologies such as AI, big data mining, and automation. GBB adheres to the corporate vision of "Global Bioprocessing Made Simpler and More Efficient," and aims to address the challenges of long timelines, high costs, and low success rates in drug development. The core team of GBB comprises experts from medicine, synthetic biology, and artificial intelligence. GBB has secured nearly 100 patents related to AI-enabled drug development and successfully commercialized multiple AI technology platforms. The company has established long-term partnerships with leading domestic and international enterprises. GBB has passed the ISO 9001:2015 quality management system certification, been selected for Forbes Asia 100 to Watch 2024 List, and won numerous awards. Great Bay Bio (GBB) was established in 2019. The company focuses on applying AI and other cutting-edge technologies to drug development and other bioprocessing industries to improve the problems of long drug development time, high cost and low success rate. The company has over 50 patent applications, including more than 40 intelligent bio platform patents. The company has completed three rounds of financing by the end of 2022, with a financing amount of more than 30 million US dollars.